Gitterman Wealth Management LLC Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Gitterman Wealth Management LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 303 shares of the biopharmaceutical company’s stock after selling 94 shares during the quarter. Gitterman Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $266,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Headlands Technologies LLC raised its position in Regeneron Pharmaceuticals by 24,760.0% in the 4th quarter. Headlands Technologies LLC now owns 1,243 shares of the biopharmaceutical company’s stock valued at $1,092,000 after buying an additional 1,238 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its position in Regeneron Pharmaceuticals by 5.9% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 89,055 shares of the biopharmaceutical company’s stock valued at $78,216,000 after buying an additional 4,954 shares during the last quarter. Stevens Capital Management LP bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $367,000. Abbrea Capital LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $235,000. Finally, Syon Capital LLC grew its stake in Regeneron Pharmaceuticals by 27.4% in the 4th quarter. Syon Capital LLC now owns 782 shares of the biopharmaceutical company’s stock valued at $687,000 after purchasing an additional 168 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on REGN shares. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Bank of America upped their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. TD Cowen upped their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Barclays increased their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $977.77.

Insider Activity

In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $7.48 during trading hours on Friday, reaching $883.20. 505,652 shares of the company’s stock traded hands, compared to its average volume of 431,865. The stock has a market cap of $96.94 billion, a PE ratio of 25.42, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The firm’s 50 day simple moving average is $948.00 and its 200-day simple moving average is $894.04. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the company posted $10.96 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.